JY
ELVN icon

Jeff Yass’s Enliven Therapeutics ELVN Stock Holding History

Jeff Yass’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Sell
3,993
-21,179
-84% -$899K ﹤0.01% 11923
2026
Q1 		$987K Buy
+25,172
New +$697K ﹤0.01% 7919
2025
Q4 		– Sell
-31,438
Closed -$644K – 12638
2025
Q3 		$644K Sell
31,438
-24,191
-43% -$488K ﹤0.01% 8400
2025
Q2 		$1.12M Buy
55,629
+10,714
+24% +$203K ﹤0.01% 7154
2025
Q1 		$884K Buy
44,915
+29,385
+189% +$632K ﹤0.01% 7557
2024
Q4 		$349K Buy
+15,530
New +$403K ﹤0.01% 9499
2023
Q2 		– Sell
-17,167
Closed -$376K – 12315
2023
Q1 		$376K Buy
+17,167
New +$349K ﹤0.01% 9219
2022
Q3 		– Sell
-24,552
Closed -$145K – 13395
2022
Q2 		$120K Sell
24,552
-4,993
-17% -$24.4K ﹤0.01% 11278
2022
Q1 		$222K Buy
29,545
+20,347
+221% +$134K ﹤0.01% 10985
2021
Q4 		$83K Buy
9,198
+6,361
+224% +$83.4K ﹤0.01% 12261
2021
Q3 		$46K Buy
+2,837
New +$58.9K ﹤0.01% 12373

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Jeff Yass's ELVN Position: Q2 2026 in Review

Jeff Yass reduced its Enliven Therapeutics (ELVN) stake by 84% in Q2 2026, selling an estimated $899K and leaving 3,993 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #11923.

Jeff Yass first reported a position in ELVN in Q3 2021 and has held it in 11 quarters since. The position peaked at $1.12M in Q2 2025. 209 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Jeff Yass held 3,993 shares of Enliven Therapeutics worth $203K as of Q2 2026.
  • Jeff Yass sold 21,179 Enliven Therapeutics shares in Q2 2026, an estimated $899K.
  • Enliven Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11923 holding.
  • Jeff Yass first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • Jeff Yass's Enliven Therapeutics position peaked at $1.12M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.